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Toxoplasma is a significant opportunistic pathogen in AIDS, and bradyzoite differentiation is the critical step in the
pathogenesis of chronic infection. Bradyzoite development has an apparent tropism for cells and tissues of the central
nervous system, suggesting the need for a specific molecular environment in the host cell, but it is unknown whether
this environment is parasite directed or the result of molecular features specific to the host cell itself. We have
determined that a trisubstituted pyrrole acts directly on human and murine host cells to slow tachyzoite replication
and induce bradyzoite-specific gene expression in type II and III strain parasites but not type I strains. New mRNA
synthesis in the host cell was required and indicates that novel host transcripts encode signals that were able to induce
parasite development. We have applied multivariate microarray analyses to identify and correlate host gene
expression with specific parasite phenotypes. Human cell division autoantigen-1 (CDA1) was identified in this analysis,
and small interfering RNA knockdown of this gene demonstrated that CDA1 expression causes the inhibition of
parasite replication that leads subsequently to the induction of bradyzoite differentiation. Overexpression of CDA1
alone was able to slow parasite growth and induce the expression of bradyzoite-specific proteins, and thus these
results demonstrate that changes in host cell transcription can directly influence the molecular environment to enable
bradyzoite development. Investigation of host biochemical pathways with respect to variation in strain type response
will help provide an understanding of the link(s) between the molecular environment in the host cell and parasite
development.
Citation: Radke JR, Donald RG, Eibs A, Jerome ME, Behnke MS, et al. (2006) Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii
growth and development. PLoS Pathog 2(10): e105. DOI: 10.1371/journal.ppat.0020105
Introduction
Toxoplasma gondii infects a multitude of warm-blooded hosts
where tachyzoite and bradyzoite life stages form in various
tissues [1]. Bradyzoite development is the critical step in the
pathogenesis of chronic Toxoplasma infection [2–4], yet the
molecular details that govern this process are not clearly
delineated. Bradyzoite development in human subjects has an
apparent tropism for cells and tissues of the central nervous
system, where clinical symptoms of toxoplasmosis are
primarily manifest. Yet in a cross section of animal models,
bradyzoite development differs radically, such that tissue
cysts can readily be found in porcine and ovine muscle but
rarely, if at all, in bovine and equine species [5–7]. The
apparent molecular discrimination of host and tissue wherein
parasite development will succeed is often underappreciated
for Toxoplasma but is an accepted principle of host–parasite
interactions in most apicomplexa species.
The molecular details that distinguish a host cell environ-
ment that inﬂuences Toxoplasma development from one that
does not are unclear. The issue of parasite growth is
interlinked with this question through the slowing of the
parasite cell cycle that precedes the initiation of the T. gondii
bradyzoite program [2,8,9]. The pathway of bradyzoite
development initiated by either sporozoite or bradyzoite
leading to the mature tissue cyst follows a progressive series
of events marked by changes in the parasite cell cycle that
ultimately lead to a growth-arrested parasite [2,9]. End-stage
bradyzoites enter a state of dormancy that may be equivalent
to the classic G0 phase with indeterminate life span, and as
such, these parasites likely require an equally long-lived host.
For these reasons, it is not surprising that tissue cysts are
observed in cells of the brain [10] and mature muscle cells of
susceptible hosts [6,11]. Whether this unique relationship,
which appears advantageous to T. gondii transmission, is
fortuitous or the result of evolutionary design is an important
question. It is now recognized that the state of host cell life or
death is altered by speciﬁc host–parasite interactions
observed across several apicomplexa models [12–15], and this
suggests that parasite survival and development require a
speciﬁc molecular environment in the host cell. It remains to
be determined whether this environment is parasite directed
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in which parasite development is most prevalent.
The development of methods to measure whole cell gene
expression has opened the potential to understand the wider
implications of host–parasite interactions. Genomic ap-
proaches to evaluate animal cell gene expression during
Toxoplasma infection indict a diverse cross section of
biochemical pathways whose importance to host–parasite
interaction is not well understood [16,17]. In these analyses, it
is difﬁcult to cull the important from the merely incidental,
and thus, measurements of the changes in host cell gene
expression without correlation to a series of deﬁnable
parasite phenotypes or characteristics are limited by the
noise in the experiments. In this report, we demonstrate that
a trisubstituted pyrrole [18,19] can inﬂuence Toxoplasma
development through alterations in host cell gene expression.
We have resolved the set of potential host genes that are
responsible for this interaction through the application of a
multivariate analyses correlating deﬁned parasite phenotypes
with changes in host cell transcription and have demon-
strated the importance of a single host gene in development.
Results/Discussion
A Trisubstituted Pyrrole Inhibits Parasite Growth and
Induces Bradyzoite Gene Expression
Small molecule screens have identiﬁed a trisubstituted
pyrrole, designated Compound 1, that dramatically slows the
replication of T. gondii [20] and is a potent inducer of the
bradyzoite-speciﬁc antigens bradyzoite-speciﬁc antigen 1
(BAG1) and cyst wall protein (Figure 1). A short treatment
with Compound 1 was as effective as continuous exposure to
induce BAG1 expression. Similar results were obtained when
host cells were pretreated with the compound or when cells
were treated after parasite infection (1- to 6-h treatments,
Figure 1A), suggesting Compound 1 may act on the host cell to
induce expression of bradyzoite-speciﬁc antigens. It is signiﬁ-
cant that early tissue cysts induced by Compound 1 in type III
strain parasites were morphologically indistinguishable from
those induced by growth in alkaline media (Figure 1B) [21,22].
This observation is further consistent with the kinetics of
induced cyst wall and BAG1 proteins when comparing
inductionwithCompound1andgrowthinalkalinepH(Figure
S1A and S1B). Compound 1, like alkaline pH, acts to change
transcription of bradyzoite genes, indicating the effects likely
occur via the natural bradyzoite pathway (induction of BAG1
andlactatedehydrogenase2[LDH2]mRNAsisshowninFigure
S1C). Similar results with respect to growth inhibition and
BAG1 expression in human foreskin ﬁbroblasts (HFF cells)
wereobservedinbothinfected HeLacellsandprimarymurine
astrocytes (unpublished data), and when using the type II
strains (Figure 1D [see ME49-B7] and Figure S1B [see
Pr¼Prugniaud]). To verify the effects of Compound 1 on the
host cell, we treated both intracellular and extracellular VEG
tachyzoites with 3 lM Compound 1 for 3 h and then moved
parasites to new monolayers (Figure 1C). In neither case do
parasites express BAG1 at levels beyond untreated controls
(less than 5%), demonstrating that BAG1 induction requires a
Compound 1–treated host cell environment. A dose effect was
evidentat0.5,1,and2lMCompound1,withdosesgreaterthan
3 lM inducing maximal BAG1 or cyst wall protein expression
(unpublished data). In addition, Compound 1 before and after
treatment slows and then arrests VEG parasite replication
within 12 h postinfection at concentrations as low as 1 lM,
where the average number of parasites per vacuole at 72 h of
postinfection is approximately four (1 lM or greater) com-
pared with approximately 70 for untreated controls (40-h
growthshowninFigure1D).Compound1alterationtothehost
cell was reversible over time, and independent monolayers
pretreated for 3 h with 3 lM Compound 1 induced only 21%
BAG1 when parasites invaded cells at 6 h after drug removal
and 5% or less BAG1 expression was observed at extended
times of recovery (12 or 24 h).
Compound 1 was less able to slow parasite replication in
the type I strains RH and GT-1 (from more than 60 parasites
per vacuoles to less than ten in Type III strains, Figure 1D). It
was further evident that type I strains express much less cyst
wall and BAG1 protein in response to treatment with
Compound 1 or culture in alkaline pH (Figure S1A and
S1B), and it is difﬁcult to detect the induction of BAG1 or
bradyzoite-speciﬁc LDH2 mRNAs in type I strains (Figure
S1C). These results demonstrate dramatic differences when
comparing strain types in cells treated with Compound 1 and
alkaline pH. These observations are in full agreement with
direct and indirect reports of type I strain differences in
bradyzoite development [21,23–32]. Thus, the relative resist-
ance of the RH strain to form cysts is commonly known [33],
and while GT-1 is capable of completing the life cycle, the
original characterization of this strain showed that cysts were
not apparent in mice before death, as readily observed in
mice infected with the type II M-7741 strain [23]. As such, the
relative resistance to the Compound 1 induction of brady-
zoite development is consistent with previously known
characteristics of type I strains.
Altogether, these ﬁndings demonstrate that the effects of
Compound 1 are limited to strain types most competent to
complete the parasite life cycle and raise questions about the
Compound 1 mechanism controlling parasite proliferation. A
ligand binding assay using tritiated Compound 1 initially
identiﬁed cGMP-dependent protein kinase (PKG) as a target
in type I RH parasites [18], and transgenic RH parasites
expressing mutant PKG were resistant to Compound 1
control as reﬂected by increased virulence in mice and
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Synopsis
Toxoplasma is a common opportunistic pathogen among immuno-
compromised populations that include subjects undergoing organ
transplant, the fetus during early gestation, and persons with AIDS.
The parasite escapes the host immune system by forming a dormant
tissue cyst, and this chronic infection, as well as the clinical
manifestation of disease, is observed primarily in cells and tissues of
the brain and eye. Although it is not yet understood how the disease
state is established, in this study researchers demonstrate that
Toxoplasma can take cues from specific changes in host cell gene
expression to initiate switching to the tissue cyst, and they discover
that a single gene, designated human cell division autoantigen-1
(CDA1), is able to impose significant influence on the course of
infection and cyst development. These studies are the first to
identify a host gene that links the molecular environment in the cell
to parasite development. It is interesting that the response to the
host cell is not uniform among parasite strains, as acutely virulent
strains appear to ignore the host and continue to proliferate until
the cell is destroyed.parasite mass in cell culture [20,34]. Recently, however, it has
been shown that Compound 1 directly inhibits extracellular
gliding motility and the invasion of RH parasites into HFF
cells but not in transgenic RH parasites expressing a drug-
resistant PKG allele [35]—suggesting that the alteration of
parasite mobility and invasion by Compound 1 is the major
action of this drug within the parasite. RH parasites carrying
a wild-type PKG allele are already resistant to the inductive
effects of Compound 1; thus, the published effects on type I
RH parasites do not adequately explain the observed
inhibition of parasite replication or induction of bradyzoite
development in type II and type III strains. As such, type I
strains appear to be naturally resistant to the Compound 1–
induced host cell environment.
Compound 1 Treatment of HFF Cells Induces New Gene
Transcription
The observed inhibition of parasite replication and the
induction of bradyzoite development pathways after infec-
tion of Compound 1–conditioned cells suggest the host cell
environment contains a transient signal that plays a critical
role in regulating the balance between parasite proliferation
and survival within the tissue cyst. To test if that signal may
result from the induction of host cell gene expression, we
blocked HFF cell transcription during Compound 1 pretreat-
ment (prior to parasite infection) with the RNA polymerase II
inhibitor 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole
(DRB) [36]. Following a 3-h pretreatment of HFF cells with
3 lM Compound 1 and 30 or 60 lM DRB, parasites were
allowed to invade treated cells and BAG1 expression was
evaluated 72 h later (Figure 2A). Results demonstrate a 50%
inhibition of Compound 1–induced BAG1 expression at 30
lM DRB and greater than 80% inhibition using 60 lM DRB.
DRB treatment alone had no affect on parasite BAG1
expression, and thus, co-treatment with DRB (and Compound
1) largely reversed the observed BAG1 expression induced by
Compound 1 alone. Importantly, the reduction of BAG1
expression caused by DRB was also accompanied by a
restoration of parasite growth, such that parasites per vacuole
reached approximately 54 in 60 lM DRB/Compound 1
cultures compared with four or fewer in Compound 1 alone
(Figure 2B). These results conﬁrm the inverse relationship
between cell cycle progression and bradyzoite gene expres-
sion [2,8,9,37] and also demonstrate that transcriptional
Figure 1. Compound 1–Induced Parasite Growth Inhibition and BAG1 Expression
(A) Parasites allowed to invade an HFF monolayer, and then treated 1, 2, 3, or 6 h with 3 lM Compound 1, express maximal levels of BAG1 after 3-h
treatment (light bars). Similar BAG1 expression was observed with host monolayers that were pretreated with Compound 1 (dark bars).
(B) Phase image of pH-induced vacuole is shown at 72 h postinfection. Following immunostaining with dolichos lectin, note the phenotypic similarities
between cyst wall formation in alkaline media and that induced by 3 lM Compound 1.
(C) Treatment of extracellular (out) or intracellular parasites (in) with 3 lM Compound 1 for 3 h was unable to induce BAG1 expression following
infection of untreated HFF monolayers (72 h postinfection). Compare percent BAG1 induction with VEG parasites that remained in a pre- or post-treated
culture for 72 h.
(D) Type I RH and GT-1 tachyzoites inoculated into Compound 1 (3 lM for 3 h)–pretreated HFF cells displayed little or no BAG1 expression (light bars),
while in type III VEG or type II ME49B7 cultures, 68% to 75% of parasites express BAG1. Note that parasite growth is dramatically affected in VEG and
ME49B7 cultures but not in RH or GT-1 parasites (black bars). The x-axis in this graph is used to plot both percent BAG1
þ and average vacuole size.
DOI: 10.1371/journal.ppat.0020105.g001
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the induction of bradyzoite development.
Compound 1 is a trisubstituted pyrrole p38a mitogen-
activated protein kinase (MAPK) inhibitor (IC50¼20 nM) [38]
with similar structure to other known MAPK inhibitors [39].
In a comparison of potency to inhibit parasite growth and
induce BAG1 or cyst wall protein expression in VEG strain
parasites, we evaluated several commercially available refer-
ence p38 MAPK inhibitors. A trisubstituted pyrazole,
designated 505126 (IC50 ¼ 35 nM; EMD Biosciences, San
Diego, California, United States) and a trisubstituted imida-
zole, designated PD169316 (IC50 ¼ 89 nM), were unable to
induce bradyzoite development at concentrations as high as
10 lM. A trisubstituted imidazole, designated SB203580 (IC50
¼34 nM), showed only partial induction (approximately 40%
parasite BAG1 expression by 72 h postinfection), but an
alternate trisubstituted imidazole, designated SB202190 (IC50
¼ 16 nM), was able to slow VEG strain parasite growth and
induce BAG1 expression similar to that observed for
Compound 1 and at concentrations as low as 30 nM (greater
than 80% BAG1
þ vacuoles and fewer than four parasites per
vacuole at 72 h postinfection). Speciﬁc parasite molecules
that mediate this response are presently unknown, but
similar to their resistance to Compound 1, the type I strains
RH and GT-1 were also resistant to pretreatment or
posttreatment with these compounds and do not slow growth
or express bradyzoite antigens in response to the treat-
ment(s) used in these experiments. Co-treatment of host cells
with both Compound 1 and SB202190 at these concentra-
tions was found to abrogate the inductive effects of either
and allowed VEG parasites to grow normally and without
induction of BAG1 or cyst wall protein (less than 10% BAG1
þ
vacuoles and an average of 60 parasites per vacuole at 72 h
postinfection). Collectively, these observations suggest that
the Compound 1 mechanism to induce parasite development
is distinct from that of SB202190. Given the relationship of
these compounds to the MAPK pathway, we assessed the
ability of lipopolysaccharide (LPS), phorbol esters (PMA)/
ionomycin, anisomycin, and parasite infection to cause the
activation of p38 MAPK by inducing phosphorylation in HFF
cells. It was evident that of these strategies for activation,
only anisomycin was able to signiﬁcantly induce p38
phosphorylation in this cell type (Figure S2A). Moreover,
combinations of parasite infection and LPS treatment were
unable to induce p38 phosphorylation above levels observed
in the untreated control (Figure S2A). We further tested the
ability of SB202190, 506126, and Compound 1 to inhibit the
activation of p38 and its ability to phosphorylate the known
downstream targets ATF-2, MAPKAP2, and Elk-1 (Figure
S2B). Results suggest that anisomycin is able to induce
signiﬁcant phosphorylation of p38, relative to the untreated
control (Figure S2B, compare C with A). Compound 1 was
able to prevent some p38 phosphorylation but had no effect
on the ability of activated p38 to phosphorylate the down-
stream target ATF-2, based on comparison with cells treated
with SB202190 and 506126. It is interesting that phosphor-
ylation of ATF-2 appears to be enhanced by treatment with
30 nM SB202190 and 506126 when compared with cells
treated with anisomycin alone and untreated controls.
Finally, anisomycin-activated p38 was unable to phosphor-
ylate either MAPKAP-2 or Elk-1 in these cells. Thus, while we
cannot yet exclude a potential role for p38 (and its
inhibition) in the observed effects of Compound 1 and other
MAPK inhibitors in this cell type, these results suggest that
other biochemical pathways play a signiﬁcant role.
Gene Expression Analyses Identify Host Cell mRNAs
Whose Expression Correlates with Compound 1 Induction
of Bradyzoite Development
To identify the host cell mRNAs affecting the observed
induction of parasite BAG1 or cyst wall protein, we used a
multivariate series of DNA microarray hybridizations (de-
ﬁned in Table 1) on RNA samples obtained from treated HFF
Figure 2. Compound 1–Induced Slowing of Parasite Growth and BAG1
Expression Is Mediated by New Host Cell Gene Transcription
(A) HFF cells were treated or co-treated for 3 h with 3 lM Compound 1
and 30 or 60 lM RNA polymerase II inhibitor DRB. Following removal of
the compounds, VEG parasites were inoculated and BAG1 expression
was evaluated 72 h postinfection. Antagonism of Compound 1 induction
of parasite BAG1 with DRB shows a dose effect when comparing co-
treatment with 30 or 60 lM DRB and 3 lM Compound 1 (DRB 30/C1 and
DRB 60/C1, respectively). DRB alone had no effect on parasite growth or
BAG1 expression, while induction by 3 lM Compound 1 (CMPND1) is
included here for reference.
(B) In untreated cultures, VEG parasites reach greater than 70 per vacuole
by 72 h postinfection (black circle), but vacuoles with an average of only
four parasites were observed in Compound 1–treated cells (grey box).
Co-treatment with 60 lM DRB restored parasite replication to
approximately 60 parasites per vacuole (black box) by 72 h postinfection,
while reducing the level of BAG1þ to 12% (dark bars) from greater than
70% in cultures treated with Compound 1 alone (light bars).
DOI: 10.1371/journal.ppat.0020105.g002
PLoS Pathogens | www.plospathogens.org October 2006 | Volume 2 | Issue 10 | e105 0967
A Host Gene Can Influence T. gondiicells (prior to infection) and we correlated changes in the
levels of host cell mRNAs with distinct developmental
outcomes that were obtained by subsequent parasite in-
fections (the full design of these experiments and list of the
ﬁnal genes along with normalized levels for each condition is
published in Table S1). By identifying those host mRNAs
whose levels were altered in predictable ways with respect to
the treatment regimens to induce parasite BAG1 expression,
we were able to reduce the relevant number of potential host
cell mRNAs. In Table 1, the range of host mRNAs from
successive queries of the database drops from 37,000 possible
genes on the array to 79 when the analyses combine
Compound 1 induction with recovery for 6 or 12 h prior to
infection, with the noninductive effects of DRB and 506126,
and with the antagonism of Compound 1 by DRB and
SB202190. The class of host cell mRNAs obtained by this
analysis suggests Compound 1 has an effect on the growth
state of the cell, as many of the mRNAs in the ﬁnal list can be
directly or indirectly associated with growth regulatory
pathways of animal cells. The best-ﬁt match (high induction
and correlation) from this class of growth regulators was cell
division autoantigen-1 (CDA1, also known as SE20–04).
Hybridization signals for CDA1 were up 47-fold in Com-
pound 1–pretreated host cells but were nearly unchanged in
cells where the effects of Compound 1 induction were
antagonized by DRB and SB202190. CDA1 is a nucleosome
assembly–related protein demonstrated to be involved in cell
cycle arrest and negative control of cell proliferation [40].
Overexpression of CDA1 in HeLa cells, similar to elevated
levels in the Compound 1–treated human ﬁbroblasts
reported here, has been shown to arrest cell growth [40].
Interestingly, CDA1 protein can be phosphorylated in vitro
by cyclin D1/CDK4, cyclin A/CDK2, and cyclin B/CDK1, and
mutation of the CDK phosphorylation sites abrogates the
negative growth effects of this protein [40]. In this context,
CDA1 was selected for initial studies to begin exploration of
host cell growth regulation and the related molecular
environment potentially linked to parasite development.
Knockdown of Host Cell CDA1 Reverses the Compound 1
Inhibition of Parasite Replication and Induction of Parasite
BAG1
To test the relevance of CDA1 to the observed Compound
1–induced growth inhibition and BAG1 expression in the
parasite, we used a small interfering RNA (siRNA) SmartPool
(Dharmakon, Lafayette, Colorado, United States) consisting
of four distinct siRNAs against various regions of the CDA1
coding sequence, to knock down mRNA levels in Compound
1–pretreated HFF cells. VEG parasites were then introduced
into this environment, and parasite vacuole size and the level
of BAG1 expression were evaluated at 48 h postinfection. It
was evident that the inhibition of parasite growth that occurs
under Compound 1 was dramatically reversed by siRNA
knockdown of CDA1 since parasite replication in these host
cells was nearly equivalent to untreated controls (Figure 3A).
Similarly, the knockdown of CDA1 mRNA reduced BAG1
expression to 16% of vacuoles from greater than 60% under
Compound 1 alone (Figure 3A). This result was speciﬁc to
CDA1 siRNA, as siRNA knockdown of Lamin A/C in HFF cells
(Figure 3B) was unable to reverse Compound 1 inhibition of
parasite growth or the elevation of BAG1 expression
(unpublished data). Knockdown of CDA1 mRNA beginning
at 24 h post-treatment (with siRNA and Compound 1) and
continuing to 72 h is demonstrated by RT-PCR (Figure 3B).
Transfection of HFF cells with LipofectAMINE or CDA1
siRNA alone was not found to inﬂuence parasite growth or
induce BAG1 expression (unpublished data).
We tested each individual siRNA in the CDA1 Smartpool
separately to corroborate the initial collective observations
(Figure 3C) and determined that the siRNAs designated 1 and
4 did not reverse the growth inhibition of 3-h Compound 1
pretreatment. In contrast, siRNAs 2 and 3 alone were each
able to abrogate the growth inhibitory effects of the
Compound 1 treatment and allow VEG parasites to reach
vacuole sizes that were 72% and 78% of that attained by the
complete Smartpool (81% of untreated controls, Figure 3C).
Antagonism of the Compound 1–induced growth inhibition
with siRNAs 2 and 3 was dose dependent as the effectiveness
of each siRNA to antagonize the Compound 1 effect was
diminished at 50 and 25 nM concentrations (unpublished
data). Altogether, these results demonstrate that knockdown
of host cell CDA1 mRNA was able to reverse the potent
effects of Compound 1 on parasite replication and bradyzoite
gene expression, indicating that a single host gene (and the
host pathway involved) is a critical component of the
molecular environment in the host that is able to trigger
parasite development. The role of host CDA1 in other
methods of bradyzoite induction is unknown due to differ-
ences in cell type response and the relative slow kinetics of
bradyzoite induction. Parasite development in HFF cells
cultured in alkaline pH is only effective when maintained for
long periods; thus, the single transfection of CDA1 siRNAs
was much less effective when parasites were continually
exposed to either Compound 1 or alkaline media (pH 8.2).
Table 1. Multivariate Microarray Analyses Were Used to Correlate Changes in the Levels of Host Cell mRNAs with Distinct Parasite
Developmental Outcomes to Identify mRNAs Most Relevant to the Compound 1 Induction of Bradyzoite Development
Pretreatment of Host Cells Search Search Combination BAG1
þ Express Number of mRNA D3-fold Relative CDA1 mRNA
Compound 1, 3 lM, 3 h pre, 0 h recovery (1) 1 only .80% 289 þ47
Compound 1, 3 lM, 3 h pre, 6 h recovery (2) 1, 2 ,50% 253 þ2
Compound 1, 3 lM, 3 h pre, 12 h recovery (3) 1, 2, 3 ,25% 213 0
DRB, control, 60 lM, 3 h pre (4) 1, 2, 3, 4 ,10% 103 þ1.2
506126, control, 30 nM, 3 h pre (5) 1, 2, 3, 4, 5 ,10% 90 0
202190 30 nM þ Compound 1, 3 lM, 3 h pre (6) 1, 2, 3, 4, 5, 6 ,10% 82 þ1.5
DRB, 60 lM þ Compound 1, 3 lM, 3 h pre (7) 1, 2, 3, 4, 5, 6, 7 ,10% 79 þ1.1
DOI: 10.1371/journal.ppat.0020105.t001
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parasite growth in HFF cultures treated prior to parasite
infection or with continuous exposure after infection
(unpublished data), a ﬁnding consistent with reported
resistance of HFF cells to this cytokine [21,41].
CDA1 Inhibits Parasite Replication and Induces Expression
and Assembly of Cyst Wall Protein
To determine if CDA1 alone was able to initiate early
bradyzoite development in type I and type III strain parasites,
we expressed CDA1 ectopically in HeLa cells and assessed
parasite growth and induced expression of cyst wall protein
at 12-h intervals to 48 h postinfection (Figure 4A). It was
evident that induced CDA1 was able to inhibit type III VEG
strain parasite replication and reduce average parasites per
vacuole beginning at 36 h postinfection, and by 48 h,
parasites in CDA1-transformed HeLa cells, which had not
been induced with tetracycline, had undergone nearly ﬁve
division cycles relative to only three complete replication
cycles in cells where CDA1 was induced by tetracycline
(compare 22 parasites per vacuole with seven at 48 h
postinfection, Figure 4A). Concurrently, 47% and 50% of
all parasite vacuoles in CDA1-transformed cultures that were
maintained in tetracycline expressed and assembled brady-
zoite cyst wall protein (Figure 4A; 36 and 48 h postinfection,
respectively). This was close to the maximum levels of cyst
wall expression we observed for Compound 1 induction in
these cells (ranges from 64% to 88%). The number of cyst
wall positive vacuoles in HeLa cells transformed with the
CDA1 plasmid but not induced with tetracycline was slightly
higher than the spontaneous levels we observed in non-
transformed HeLa cells (8% spontaneous) or in HeLa cells
transformed with a tetracycline-regulated YFP gene (9% with
or without tetracycline), suggesting that there is some leaky
expression of CDA1 from this plasmid. No induction of cyst
wall expression beyond spontaneous levels was seen in VEG-
infected HeLa cells treated with tetracycline alone. Collec-
tively, these results demonstrate that CDA1 alone was able to
slow parasite growth and induce expression of a bradyzoite-
speciﬁc antigen similar to that observed for Compound 1
treatment. In contrast, but as expected, primary type I GT-1
parasites (less than 12 passages) were unresponsive to the
overexpression of CDA1 in the host cell and were able to
grow normally (Figure 4B)—an observation consistent with
the observed growth of type I strains in the Compound 1–
altered cell.
Summary
It is widely accepted that treatments to induce bradyzoite
development act speciﬁcally on the parasite [21,29,42,43],
although host cell inﬂuences on this process cannot be ruled
out and may, in fact, be evident in the clinical pathologies
where tropisms for speciﬁc tissues of the central nervous
system and the eye are prevalent [6,44,45]. The results
presented here are consistent with this view as Compound 1
Figure 3. siRNAs against CDA1 Antagonize Compound 1 Inhibition of
Parasite Growth
(A) HFF cells transfected with the siRNA SmartPool against CDA1 and co-
treated with Compound 1 prior to parasite infection allow normal
parasite growth (black boxes) and BAG1 expression (dark bars). Compare
growth in untreated controls (black circles) with growth (grey boxes) and
BAG1 expression (light bars) in Compound 1–treated cells.
(B) Concurrent with the restoration of normal parasite growth and BAG1
expression, we observed the loss of Compound 1–induced CDA1 mRNAs
as measured by RT-PCR of total RNA at 24, 48 following transfection with
siRNA and Compound 1 pretreatment. Lamin A/C controls demonstrate
siRNA-mediated knockdown of individual genes. Transfection with
siRNAs against Lamin A/C, with nonspecific siRNAs or with Lipofect-
AMINE alone, was unable to antagonize Compound 1 inhibition of
parasite growth or induction of BAG1 expression (results not shown). RT-
PCR primers specific to GAPDH were used as a control for RNA quality.
RT-PCR experiment: C¼ Compound 1 pretreatment (3 h/3 lM) only; E ¼
HFF cells pretreated with both Compound 1 and siRNA(s) against either
CDA1 or Lamin A/C. Protein blot: L ¼ HFF cells pretreated with
LipofectAMINE, but without siRNAs; si¼HFF cells pretreated with siRNAs
against either CDA1 or Lamin A/C, but without transfection reagent
(LipofectAMINE); E ¼ same as above.
(C) Co-transfection of HFF cells with siRNAs 1 to 4 separately and then
treatment with Compound 1 prior to parasite infection demonstrate that
siRNAs 2 and 3 were responsible for antagonizing the Compound 1–
induced inhibition of parasite growth as measured by average parasites
per vacuole at 48 h postinfection. Compare light bars for siRNAs 2 and 3
with untreated parasites (labeled no siRNA), and also with Compound 1–
treated parasites (labeled Compound 1). siRNAs 1 and 4 do not
significantly antagonize the Compound 1–induced inhibition of parasite
replication.
DOI: 10.1371/journal.ppat.0020105.g003
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contribute to a molecular environment that causes the
parasite to initiate bradyzoite development. Other published
methods to trigger bradyzoite formation may also act through
the host as we have found that long-term preconditioning of
HFF cells in alkaline media can induce some bradyzoite gene
expression in parasites that invade this altered environment
but are then maintained under physiological pH. Parasite
growth and the expression of acknowledged bradyzoite-
speciﬁc BAG1 and cyst wall mRNA and proteins in the
Compound 1 and pH-altered HFF environment are consistent
with elevated levels of these mRNAs in in vivo cysts [46] and
during sporozoite initiated development [47] and suggest we
have described an authentic bradyzoite development pathway.
It is intriguing that type I RH and GT-1 parasites were
resistant to the Compound 1–altered host cell environment
and were unable to slow growth signiﬁcantly, express BAG1,
or assemble a cyst wall. It is unclear whether this resistance is
related to reported differences in development among strain
types [21,23–32], but it is possible that type I strains respond
to different stimuli. Alternatively, the distinct developmental
phenotype of type I strains may be the result of a dominant
mutation that lessens the response of these strains to a host
environment that otherwise slows growth and initiates para-
site development in type II and type III strains. Phenotypic
differences between strains when assessing inherent growth
r a t e ,v i r u l e n c e ,t i s s u em i g r a t i o n ,a n dt h ei n d u c t i o no f
cytokines appear to be inherited [32]; such that differences
in persistence are likely to also have a genetic basis.
Consistent with this concept, we have found that F1 progeny
from a type I 3 type III genetic cross show development
phenotypes that are similar to one or the other parent
(Michael White, Montana State University, and L. David
Sibley, Washington University, unpublished data), and we
have recently transferred Compound 1 resistance to type III
CTG parasites using genetic complementation with a type I–
speciﬁc RH strain cosmid library (Jay Radke and Michael
White, Montana State University, unpublished data). Com-
bined, these observations suggest a genetic mechanism may
underlie observed developmental differences in type I strains.
We have used a novel multivariate approach using micro-
array hybridizations to successfully identify host cell pathways
most relevant to the observed Compound 1–induced brady-
zoite development. Through the use of siRNA knockdown
methods, we have conﬁrmed that increased expression of at
leastoneofthehostgenesalteredbyCompound1isrequiredto
arrest the parasite cell cycle and induce bradyzoite gene
expression. The inhibition of parasite growth and the
induction of cyst wall protein in cells where CDA1 is overex-
pressed suggest an important, although unknown, role for
CDA1 in the host–parasite interaction leading to bradyzoite
development. These results are congruent with the discovered
effects of the HIF1 hypoxia response gene required for growth
of tachyzoites in a low oxygen environment (3%, [48]) and
suggest that other host cell proteins may play critical roles in
thepathogenesisofToxoplasmainfection.AlongwithCDA1,the
ﬁnalgenelistfromTableS1includesvariousotherfactorswith
demonstrated roles in the proliferative state of the host cell
suggesting the growth state of the cell may help deﬁne a host
environment as more (or less) suitable for parasite develop-
ment. How the parasite biochemically registers the growth
status of the cell is unknown but ﬁts the observation that
parasitetissuecysts areprimarily distributed indifferentiated,
long-lived cells such as mature skeletal muscle and brain
neurons[45].Furtherinvestigationofthesehostpathwayswith
respect to variation in strain response will increase our
understanding of the potential links between the cell cycle
state of the host cell and parasite development.
Materials and Methods
Parasite culture in human foreskin ﬁbroblasts. Tachyzoites of VEG
(type III strain), ME49 (type II strain), and RH and GT-1 strains (both
type I) were maintained separately by serial passage in HFF, and these
cells were cultured in Dulbecco’s modiﬁed Eagle medium (DMEM;
Figure 4. Overexpression of CDA1 in Infected Cells Slows Parasite
Growth and Induces Bradyzoite Development
(A) HeLa cells expressing the tetracycline repressor protein transfected
with the pcDNA4 TO-CDA1 plasmid inhibit parasite growth and induce
cyst wall protein when grown in media containing tetracycline to induce
expression of the CDA1 transgene. Compare parasite growth in
transfected HeLa cells cultured without tetracycline (growth measured
as average parasites per vacuole, PPV, open box with lines) with that of
parasite growth in media containing tetracycline to induce CDA1
expression (shaded box with lines). Concurrent with the observed
inhibition of parasite replication, cyst wall protein was also expressed.
Compare background levels of cyst wall protein (light bars) with levels
induced by overexpression of CDA1 (dark bars) at 36 and 48 h. Treatment
of HeLa cells with tetracycline alone, transfection of HeLa cells with the
pcDNA4 TO expression vector alone, or transfection of HeLa cells with
the pcDNA4 TO vector and induced to expressed the coding sequence
for yellow fluorescent protein (YFP) were all unable to slow parasite
growth or induce the expression of cyst wall protein (unpublished data).
(B) Early passage type I GT-1 parasites (fewer than 12 passages from the
oocyst) do not slow growth or initiate the expression of bradyzoite-
specific cyst wall protein in a cell expressing CDA1 under control of the
tetracycline-inducible promoter. Compare parasite growth and cyst wall
protein measured by immunofluorescence in uninduced cells (open
boxes, light bars) with growth and cyst wall protein in cells ectopically
expressing the CDA1 protein (shaded boxes, dark bars).
DOI: 10.1371/journal.ppat.0020105.g004
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with 1% (v/v) newborn calf serum (Hyclone Laboratories, Logan,
Utah, United States) as previously described [8]. To harvest
tachyzoites, infected HFF monolayers were scraped from culture
ﬂasks, needle-passed, and ﬁltered using a 3-lm nucleopore mem-
brane to separate parasites from host cell debris. These parasites were
then pelleted (15 min at 2,500 rpm; Sorvall ST-6000), resuspended in
fresh media, counted, and diluted for the experimental infections
described below.
BAG1 immunoﬂuorescence and parasite growth assays. Parasite
BAG1 expression was evaluated by IFA in HFF cells cultured in eight-
well slides as previously described [2,8]. Conﬂuent monolayers were
cultured in 1% DMEM containing concentrations of Compound 1
ranging from 0.5 to 10 lM for 3 h and then washed extensively with
normal media prior to tachyzoite infection. Parasite BAG1 expres-
sion was measured by IFA at 12-h intervals to 72-h postinfection
using monoclonal antibody against the antigen [42]). Fluorescence
was evaluated using an epiﬂuorescence microscope (Eclipse TE300;
Nikon, Melville, New York, United States), and images were collected
with a digital camera (SPOT; Dynamic Instruments, Sterling Heights,
Michigan, United States). Percent BAG1
þparasites was determined by
counting the BAG1
þ vacuoles in 100 randomly selected ﬁelds.
Staining of cyst wall protein was completed using antibody against
Dolichos lectin as previously described [49]. VEG strain tissue cysts
were induced in vitro using (1) 48-h growth in alkaline media (pH 8.2)
[26] or, separately, (2) 72-h treatment postinfection in 3 lM
Compound 1. In all analyses where parasite growth was monitored,
growth rate was evaluated by parasites per vacuole using the average
number of parasites in 100 vacuoles, calculated at 12-h intervals
postinfection [8].
Western analyses. Western blot analyses were performed essen-
tially as previously described [50] for (1) detection of phosphory-
l a t e dp 3 8M A P Ka n da s s o c i a t e dd o w n s t r e a mt a r g e t s ,( 2 )t h e
detection of the BAG1 protein in parasites grown in HFF cells
treated with Compound 1 or alkaline pH (pH 8.2), and (3)
assessment of Lamin A/C protein control in the siRNA knockdown
of CDA1. (1) For assessment of MAPK and associated proteins,
lysates from cell monolayers pretreated with Compound 1, 202190,
506126, or alkaline media (pH 8.2) and co-activated with anisomy-
cin, LPS, or PMA/ionomycin were ﬁxed using M-PER (product No.
78501; Pierce Chemical, Rockford, Illinois, United States) containing
protease inhibitors and according to the manufacturer’s protocol.
Protein concentration was assessed using bicinchoninic acid assay
(BCA assay, product No. 23225; Pierce Chemical), and 10 to 50 lgo f
total protein per lane was resolved using 7% to 15% SDS-PAGE.
Separated proteins were transferred to nitrocellulose, and the
transferred blot was then blocked for 1 h at room temperature (RT)
using 5% milk in Tris-buffered saline (pH 7.4) containing 0.01%
Tween-20 (TBST). The blot(s) was incubated overnight at 4 8C
separately with one of several primary antibodies against p38,
phospho-38, phospho-MAPKAP2, phospho-ATF-2, or phospho-Elk1
(product No. 9913; Cell Signaling Technology, Danvers, Massachu-
setts, United States), diluted 1:1,000 in 0.5% milk in TBST. Blots
were washed three times in TBST for 15 min and then incubated 4
h at RT with anti-rabbit IgG–horseradish peroxidase conjugate
(HRP) diluted 1:2,500 in 0.5% milk in TBST. Protein bands were
detected via enhanced chemiluminescence (ECL) reagent and x-ray
ﬁlm. (2) To detect parasite BAG1, tachyzoites were obtained from
infected HFF monolayers grown in alkaline pH (pH 8.2) by scraping
and needle-passing to disrupt host cells and then puriﬁed by
ﬁltration through a 3.0-lm Nucleopore ﬁlter. Parasite proteins were
extracted by adding NP-40 to a ﬁnal concentration of 2% (v/v). The
resulting lysate was then incubated on ice for 30 min, followed by
centrifugation for 10 min at 12,000 3 g. The supernatant was mixed
with nonreducing buffer, and proteins were resolved by SDS-PAGE
and transferred to nitrocellulose. The transferred blot was blocked
for 1 h in 5% (w/v) nonfat dry milk in 50 mM Tris (pH 8.0) and 150
mM NaCl and then probed for at least 1 h with the primary
monoclonal antibody against BAG1 [42] diluted 1:500 in 0.5% milk
as described above. The blot was washed three times for 15 min in
blocking buffer, and proteins were visualized by incubating the blots
in anti-mouse IgG alkaline phosphatase–conjugated antibody for 1
h, washing as above, and protein visualized by conversion of 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium with
localized antibody–alkaline phosphate conjugate according to
standard methods (product No. 2209; Invitrogen, Carlsbad, Cal-
ifornia, United States) [51]. (3) We assessed Lamin A/C control
protein in the siRNA knockdown using 3 lg of total protein
resolved via 10% SDS-PAGE and transferred to nitrocellulose. The
transferred blot was blocked overnight at 4 8C in TBST containing
10% horse sera and probed 3 h in blocking buffer at RT with
primary anti-mouse IgG monoclonal antibody against Lamin A/C
(1:1,000; BD Biosciences, Woburn, Massachusetts, United States).
The blot was washed three times for 5 min in TBST, and blots were
incubated for 2 h in blocking solution with secondary anti-mouse
IgG alkaline phosphatase conjugate (1:10,000; Promega, Madison,
Wisconsin, United States). Blots were washed and protein visualized
using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
methods as described above.
Microarray analysis of Compound 1–induced gene expression.
Total RNA was isolated from HFF cells using Qiagen RNeasy spin
columns according to standard protocols (Qiagen, Valencia, Cal-
ifornia, United States). Cells were treated using Compound 1
treatment regimens known to induce parasite BAG1 but also using
alternate p38 MAPK inhibitors known to antagonize the Compound 1
effects on BAG1 expression, as well as treatment with inhibitors of
RNA polymerase II. Total RNA was evaluated using the Agilent
Bioanalyzer (Agilent Technologies, Palo Alto, California, United
States), and mRNA levels were characterized by hybridizations with
the Human Oligo 1A and 1B microarrays (Agilent Technologies;
ServiceXS, Leiden, the Netherlands). Total RNA (5 lg) was used to
prepare double-stranded cDNA using T7-(dT)24 primer and MMLV
reverse transcriptase according to standard protocols (Agilent
Technologies), and cDNA was transcribed independently in the
presence of Cy5- and Cy3-labeled UTP and CTP and labeled cRNA
puriﬁed using Qiagen RNeasy Kit. Puriﬁed cRNA was fragmented to
less than 200 bases by incubation for 30 min at 60 8C in fragmentation
buffer and hybridized with the Agilent Human Oligo 1A and 1B slide
arrays for 17 h at 60 8C. The Human Oligo 1A and 1B slide arrays
contain 47,000 sequences selected from GenBank, dbEST, and RefSeq
and the clusters created from the UniGene database. Arrays contain
60-bp oligonucleotides and most probe sets are duplicated. Each
array contains internal probe sets that serve as controls for
monitoring RNA integrity. The protocol includes two posthybridiza-
tion washes, staining, and a post-stain wash. Arrays were scanned
twice, and hybridization intensities were collected from scanned
images. Gene expression data were extracted with GeneSpot and
Gene Spring (Silicon Genetics, San Diego, California, United States)
expression analysis software. For each treatment to induce parasite
development, the treatment itself, e.g., Compound 1, DRB, SB202190,
etc., the annotated sequence name for each spot on the array, and the
induction (or not) of parasite BAG1 expression were stored
separately in a unique ﬁeld within a mySQL relational database. A
single mySQL database contained all hybridization results. The
database was then queried for mRNAs that were changed 3-fold or
greater as a result of the treatment and whose regulation was
coincident with observed inhibition of parasite growth and BAG1
expression in the parasite.
Gene knockdown using siRNA. HFF cells (4310
4) were transfected
in 150-ll suspensions (1% DMEM without FBS) per well of an eight-
well slide with 25 to 150 nM siRNA in Opti-MEM (Invitrogen) and
LipofectAMINE 2000, according to the manufacturer’s instructions
(Invitrogen). The siRNA against CDA1 was a Smartpool of four
distinct siRNAs against alternate segments of the coding sequence
(Dharmacon). siRNAs against Lamin A/C [52] were used to demon-
strate siRNA activity in primary HFF (positive control) and also to
ensure that transfection of siRNAs unrelated to Compound 1–
induced parasite growth inhibition and BAG1 expression was not
able to induce this parasite phenotype alone (negative control). To
transfect siRNAs into cells, HFF cells were incubated for 6 h at 37 8C
(5% CO2) with 25 to 150 nM siRNAs in LipofectAMINE and Opti-
DMEM (without serum or antibiotics, total volume 150 ll per well of
an eight-well slide; Invitrogen). After 6 h, maximum transfection was
complete and FBS was added back to a ﬁnal concentration of 10%.
Transfected cells could be incubated up to 96 h at 37 8C (5% CO2)
without appreciable loss of siRNA. Transfection of the siRNA was
completed 6 h immediately prior to parasite infection, and at 3 h
preinfection, the Compound 1 was added (3 lM ﬁnal concentration; 6
h total time for transfection of siRNA and Compound 1 treatment).
Parasites were then allowed to invade 2 h, and then parallel eight-well
slides were ﬁxed at 24-h intervals to 72 h for analysis of BAG1
expression by IFA as described above. Parasite growth was also
evaluated in these same slides using average parasites per vacuole. To
evaluate mRNA levels for CDA1 and GAPDH and mRNA and protein
levels for Lamin A/C, total RNA or cell lysates were isolated from 24-
well plates infected in concert with the eight-well slides used for
BAG1 expression and analysis of parasite growth.
RT-PCR analyses. RT-PCR was used (1) to assess mRNA levels for
GAPDH, CDA1, and Lamin A/C during siRNA knockdown of CDA1
in the Compound 1–induced host cell and (2) to assess the level of
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1. (1) Total RNA from a single well of a six-well plate was isolated
using an RNeasy spin column according to the manufacturers
protocol (Qiagen) and ﬁrst-strand cDNA synthesis completed using
less than 1 lg of total RNA and SuperScript reverse transcriptase
according to the manufacturer’s protocol (Invitrogen). PCR ampli-
ﬁcation of gene-speciﬁc target sequences was done using Platinum
Taq (Invitrogen) and primers speciﬁc to GAPDH (forward 59-
tcatccatgacaactttggtatcg-39, reverse 59-gagcttgacaaagtggtcgttga-39
[53]), Lamin A/C (forward 59-aacttcaggatgagatgctgcg-39, reverse 59-
gtccagaagctcctggtactcgt-39), and CDA1 mRNAs (forward 59-aattt-
caattttgatcaaccgacg-39, reverse 59-aggattctcgctgtcgcagat-39). GAPDH
transcripts were ampliﬁed using 30 rounds of temperature cycling,
each for 30 s at 94 8C, 30 s at 58 8C, and 1 min at 72 8C, followed by
a single extension for 10 min at 72 8C. CDA1 and Lamin A/C
transcripts were ampliﬁed using annealing temperatures of 52 8C
and 55 8C, respectively. Ampliﬁcation products were resolved using
agarose gel electrophoresis and ethidium bromide staining. (2) We
also used semiquantitative RT-PCR [54,55] to assess mRNA levels for
BAG1 and LDH2 in cells treated with Compound 1. Following ﬁrst-
strand cDNA synthesis from 1 lg of total RNA as described above,
PCR ampliﬁcation of gene-speciﬁc target sequences was done using
Platinum Taq (Invitrogen) and primers speciﬁc to a-tubulin
(forward 59-tcgacaaacgaggccatctacgacatctgcc-39,r e v e r s e5 9-acca
tagccctcctcttcaccttcaccttc-39), BAG1 (forward 59-gctttgcg
ccccctgaatcctcgaccttga-39, reverse 59-gtaagcccgtttgctctggcgtactaccct-
39), and LDH2 (forward 59-gggaagagtgacaaggagtggagcagaaac-39,
reverse 59-ccaccacgtcatcaactgacttcctgaaac-39) target sequences. To
enable semiquantitative assessment of these mRNA levels, 4-fold
serial dilutions of the ﬁrst-strand cDNA were completed prior to
ampliﬁcation. a-Tubulin, BAG1, and LDH2 ampliﬁcations were all
completed from the same cDNA, made from total RNA from either
untreated parasites or from parasites grown in Compound 1. BAG1
and a-tubulin transcripts were ampliﬁed using 25 rounds of
temperature cycling, each for 30 s at 94 8C, 30 s at 62 8C, 1 min
at 72 8C, followed by a single extension for 10 min at 72 8C. For
LDH2, the annealing temperature was lowered to 55 8C and
extension for 1.5 min at 72 8C in each round of ampliﬁcation. a-
Tubulin mRNA is expressed equally in tachyzoites and bradyzoites
and was used in these studies as a PCR control.
Regulated expression of the CDA1 transgene in HeLa cells. The
sequence encoding the human CDA1 mRNA was obtained from
American Type Culture Collection (the American Type Culture
Collection [http://www.atcc.org] sequence encoding the human
CDA1 mRNA was gb VC024270 [ATCC designation ¼ 7520908, the
I.M.A.G.E. ¼ 2819684], and the T-REX tetracycline-inducible ‘‘tet-
on’’ expression system was used according to manufacturer’s
protocol (Invitrogen). A Gateway (Invitrogen) recombination ex-
pression plasmid was ﬁrst created by cloning a reading frame
cassette into the EcoRV site of the pcDNA4/TO TET-inducible
plasmid vector to prepare a destination vector for recombinational
cloning of the coding sequence (Invitrogen). The sequence encoding
CDA1 mRNA was ampliﬁed from the plasmid vector using the
primers (attB1 CDA1 forward 59-ggggacaagtttgtacaaaaaagcaggcttcgc-
catggaccgcccag-39 and attB2SE20–4 reverse 59-ggggaccactttgtacaa-
gaaagctgggtcttatccggttttccccctcttc-39) and PFU and the product
cloned by BP recombination into pDONR221 to create an entry
clone. LR recombination with the destination vector generated the
pcDNA4/TO expression vector containing the complete CDA1
coding sequence under control of the tetracycline operator
sequences and the cytomegalovirus promoter sequence (Invitrogen).
HeLa cells expressing the tetracycline repressor protein (7 3 10
6,T -
Rex; Invitrogen) were combined in 400 ll of Opti-MEM with 17.5
mg of plasmid and 12.5 mg of salmon sperm DNA and electro-
porated at 850 lF, 260 V, and 720 X in a 4-mm gap cuvette using a
BTX ECM630 electroporator (BTX Instrument, Holliston, Massa-
chusetts, United States). Cells were cultured overnight in 10% TET-
free DMEM at 37 8Ci n5 %C O 2 and then washed with HBSS, lifted
from plastic with 13 trypsin, and counted. Under these conditions,
more than 80% of host cells are transfected with the plasmid based
on parallel transfection with a tetracycline-regulated YFP plasmid
and greater than 15-fold induction of CDA1 by quantitative RT-
PCR. Approximately 60,000 HeLa cells were plated onto each well
of an eight-well slide and cultured 6 h prior to infection with
100,000 tachyzoites (type III VEG or CTG and type I GT-1 or RH).
Parasites were allowed to invade for 1 h, and remaining free
parasites were washed from the monolayer. Expression of the CDA1
transcript was immediately induced by addition of tetracycline (1
lg/ml) to the growth media. To maintain tetracycline-induction,
media containing this antibiotic were refreshed at 24-h intervals
throughout the 48-h time course.
Supporting Information
Figure S1. The Induction of BAG1 mRNA and BAG1 and Cyst Wall
Proteins Was Similar in Cells Treated with Compound 1 and Alkaline
pH
(A) Compound 1 and alkaline pH (pH 8.2) have similar effects on type
III CTG tachyzoites when measuring cyst wall protein by immuno-
ﬂuorescence assay at 40 h postinfection. Both alkaline pH and
Compound 1 were signiﬁcantly less able to induce cyst wall protein in
the type I GT-1 strain (compare cyst wall expression between type I
GT-1 and type III CTG strains under Compound 1 and pH 8.2
induction).
(B) Similar results were observed when comparing BAG1 protein
levels induced by Compound 1 or alkaline pH (pH 8.2) in type III
strain CTG and type II Prugniaud with the type I GT-1 strain
parasites at 48 and 72 h postinduction.
(C) RT-PCR from 1 lg of total RNA was used to compare levels of
BAG1 and LDH2 mRNA in type I GT-1 and type III CTG strain
parasites grown in Compound 1. Products were resolved via 1%
agarose gel electrophoresis and visualized by ethidium bromide
staining. BAG1 or LDH2 mRNAs were undetectable in type I GT-1
parasites exposed to Compound 1, while these mRNAs are clearly
induced in the type III CTG parasites. Compare RT-PCR products for
BAG1 mRNA ampliﬁcation in lanes 1 to 4 (untreated cells) with lanes
1 to 5 (3 h Compound 1 treatment) for CTG and GT-1 parasites.
Lanes 1 to 4 and lanes 5 to 8 represent 4-fold serial dilutions of the
ﬁrst-strand cDNA from untreated and Compound 1–treated para-
sites. a-Tubulin mRNA is expressed equally in tachyzoites and
bradyzoites and is presented here as a PCR control.
Found at DOI: 10.1371/journal.ppat.0020105.sg001 (141 KB JPG).
Figure S2. Assessment of p38 MAPK Activation in Compound 1–
Induced Parasite Development
(A) LPS (100 ng/ml) and PMA (20 ng/ml and ionomycin 0.5 lg/ml) were
unable to induce signiﬁcant phosphorylation of p38 MAPK in HFF as
measured by anti–phospho-p38 antibodies and Western blot.
Compare untreated cell lysates, labeled C, with those from cells
treated from 10 min to 24 h. In contrast, anisomycin (10 lg/ml) was
able to induce signiﬁcant levels of phosphorylated p38 in these cell
types, and as early as 15 min post-treatment. Parasite infection alone
was unable to induce phosphorylation of p38 (compare lysates from
the uninfected control, labeled C, with lysates from infected cells [P],
and also with lysates from treatment with LPS [100 ng/ml, L]). The
phosphorylation state of p38 was unaffected by co-treatment of
parasite-infected cells, or LPS-treated cells (100 ng/ml), and the p38




(B) HFF cells treated with anisomycin effectively phosphorylate p38
MAPK (compare untreated control cell lysates, labeled C, with lysates
from cells treated 15 min with anisomycin, labeled A). Note that 3-h
treatment with Compound 1 (labeled C1) or the known inhibitors of
p38 MAPK SB202190 (labeled 20) and 506126 (labeled 50) prior to
activation with anisomycin was unable to effect the observed
induction of p38 phosphorylation. Signiﬁcantly, anisomycin-treated
cells were unable to mediate phosphorylation of the known p38
MAPK targets MAPKAP2 and Elk1, and while ATF-2 was phosphory-
lated, co-treatment with SB202190, SB506126, or Compound 1 was
unable to alter or reduce the level of phosphorylation.
Found at DOI: 10.1371/journal.ppat.0020105.sg002 (209 KB JPG).
Table S1. Fold-Change in mRNA Levels as Measured by Hybridization
Signal Intensities during Host Cell Treatment with Compound 1, the
p38a MAPK Inhibitors 506126 and 202190, and DRB
Found at DOI: 10.1371/journal.ppat.0020105.st001 (200 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for CDA1 (also known as SE20–04) is NM_022117 and for Lamin
A/C is NM_005572.
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